Clinical trial
Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP)
NCT04275414 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP)
- Lead sponsor
- Qilu Hospital of Shandong University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 15, 2020
- Completion date
- May 2, 2020
- Enrollment
- 27 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.